Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
August 25, 2025PamplonaIn recruitment
PLATFORMPACAN1001 Ensayo clínico para la continuación del tratamiento del estudio y el seguimiento de la seguridad. [SP]
Clinical trial for continuation of study treatment and safety monitoring. -
August 18, 2025Pamplona/MadridIn recruitment
J2N-MC-JZNZ Clinical trial to determine the dose of Pirtobrutinib in adults with immune thrombocytopenia
The main objective is to ensure the safety and efficacy of Pirtobrutinib in patients with immune thrombocytopenia, and to select the doses for part 2 of this study. -
August 7, 2025Pamplona/MadridIn recruitmentEarly phase
ASTX030-01 Study of ASTX030 (cedazuridine in combination with azacitidine) in MDS, CMML or AML
The purpose of this study is to analyze the levels of the experimental drug ASTX030 in their blood, to assess the safety and tolerability of the drugs, and to find out how the participants respond to the drug. -
August 5, 2025Pamplona/MadridIn recruitmentEarly phase
YL201-INT-101-01 Clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of YL201 as a single drug and in combination with other anticancer treatments in patients with advanced solid tumors
The main goal of this study is to examine YL201 in monotherapy (part 2 participants) or in combination with atezolizumab (part 3 participants) at different doses, to find out if the study treatment is safe, to understand how the body processes the study treatment, and to understand what the study treatment does to the body and its cancer. -
July 29, 2025Pamplona/MadridIn recruitment
APG2575MG301 A global, multicenter, double-blind, randomized, Phase 3 registration study of Lisaftoclax (APG-2575) in combination with azacitidine (AZA) in patients with newly diagnosed higher-risk myelodysplastic syndrome
This study is designed to evaluate the difference in efficacy and safety of lisaftoclax, also known as APG-2575, in combination with azacitidine (AZA), compared to a placebo equivalent of APG-2575 in combination with AZA. The placebo is a treatment with no active ingredients. APG-2575 in combination with AZA or placebo equivalent of APG-2575 in combination with AZA are referred to as "study drugs." -
July 29, 2025Pamplona/MadridIn recruitmentEarly phase
GO44537 Clinical trial to evaluate the safety, pharmacokinetics and activity of RO7656594 in patients with advanced or metastatic prostate cancer
The aim of this study is to evaluate RO7656594 at different doses to determine if it is safe and how it is processed by your body. The study consists of two parts: a dose-finding stage and a scale-up stage. -
July 29, 2025Pamplona/MadridIn recruitment
75276617AML3001 Clinical trial of bleximenib, venetoclax and azacitidine for the treatment of newly diagnosed acute myeloid leukemia patients with KMT2A rearrangements or NPM1 mutations who are ineligible for intensive chemotherapy
The aim of this study is to help researchers better understand the potential efficacy and safety of BLEXIMENIB (also known as JNJ-75276617) in patients with newly diagnosed acute myeloid leukemia (ND-AML) with KMT2A or NPM1 DNA abnormalities when administered in addition to reference drugs, venetoclax and azacitidine. -
July 29, 2025Pamplona/MadridIn recruitment
D516KC00001 Clinical trial of Dato-DXd, with or without osimertinib, versus platinum derivative chemotherapy in participants with locally advanced or metastatic EGFR-mutated non-small cell lung cancer
The objective of this study is to evaluate whether Dato-DXd alone (monotherapy), or in combination with osimertinib, can safely allow longer disease control compared to the current gold standard treatment (GT) option of chemotherapy in patients who have failed prior osimertinib treatment. -
July 28, 2025PamplonaIn recruitmentEarly phase
90301900NSC2001 Phase II study of JNJ-90301900 with chemoradiotherapy and durvalumab in non-small cell lung cancer
The purpose of this study is to evaluate the injection of the radiation enhancer JNJ-90301900 into their cancer prior to concomitant chemoradiotherapy (cCRTc) followed by immunotherapy (ITc) compared to cCRT alone followed by ITc to help researchers learn more about the potential efficacy and safety of JNJ-90301900 in patients with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC). -
July 28, 2025Pamplona/MadridIn recruitment
M22-003 Phase 3 clinical trial to evaluate the safety and efficacy of epcoritamab rituximab and lenalidomide (R2)
The aim of this study is to see if the combination of the study drug epcoritamab with rituximab and lenalidomide has a better response rate than standard chemoimmunotherapy in the treatment of follicular lymphoma